"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Subsys Side Effects Center
Medical Editor: Melissa Conrad Stöppler, MD
Subsys (fentanyl) sublingual spray is indicated for the treatment of breakthrough cancer pain (BTCP) in opioid-tolerant adult patients who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Subsys is a liquid medicine that is sprayed underneath your tongue (sublingual) and allowed to absorb. Subsys can cause serious side effects, including breathing problems that can become life-threatening as well as the potential for abuse or addiction. The most common side effects of Subsys are nausea, vomiting, sleepiness, dizziness, and headache. Subsys may interact with drugs that may cause sleepiness (such as other pain medicines), anti-depressants, sleeping pills, anti-anxiety medicines, antihistamines, and muscle relaxants or tranquilizers. Patients should not drink alcohol while taking Subsys.
Subsys is dosed as one to two sprays given underneath the tongue.
Subsys may cause serious harm to unborn babies. Subsys can also pass into breast milk and cause serious harm to babies. Patients should not use Subsys while breastfeeding.
Our Subsys Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Subsys FDA Prescribing Information: Side Effects
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of SUBSYS has been evaluated in a total of 359 opioid-tolerant patients with breakthrough cancer pain. The duration of SUBSYS use varied during the open-label study. Safety data from a long-term extension study showed that the average duration of therapy in the open-label study was 66 days. The maximum duration of therapy was 149 days. The dose range studied in these trials ranged from 100 mcg per dose to 1600 mcg per dose.
The most commonly observed adverse reactions seen with SUBSYS are typical opioid side effects such as nausea, vomiting, somnolence, and constipation. Expect opioid side effects and manage them accordingly.
The most serious adverse reactions associated with all opioids including SUBSYS are respiratory depression (potentially leading to apnea or respiratory arrest), circulatory depression, hypotension, and shock. Follow all patients for symptoms of respiratory depression.
The most common adverse reaction leading to discontinuation of SUBSYS was nausea. There were also adverse reactions of abdominal distension, anorexia, confusional state, disorientation, somnolence, and constipation.
The clinical trials of SUBSYS were designed to evaluate safety and efficacy in treating breakthrough cancer pain; all patients were also taking concomitant opioids, such as sustained-release morphine or transdermal fentanyl, for their persistent cancer pain. The adverse event data presented here reflect the actual percentage of patients experiencing each adverse effect among patients who received SUBSYS for breakthrough cancer pain along with a concomitant opioid for persistent cancer pain.
Table 2 lists adverse reactions with an overall frequency of 5% or greater that occurred during titration in the clinical trials. Adverse reactions are listed in descending order of frequency within each system organ class.
Table 2: Percent of Patients with Specific Adverse
Events During Titration in the Clinical Trials (Events in 5% or More of
|System Organ Class||Titration
|Nervous System Disorders|
|A patient was counted only once within each category.|
The following adverse reactions occurred during titration in the clinical trials with an overall frequency of 1% or greater and are listed in descending order of frequency within each system organ class.
Cardiac Disorders: Tachycardia
Gastrointestinal Disorders: Diarrhea, stomatitis, dry mouth
General Disorders and Administration Site Conditions: Application site irritation, pyrexia, edema peripheral, fatigue, asthenia
Metabolism and Nutrition Disorders: Decreased appetite
Psychiatric Disorders: Depression, confusional state, hallucination, insomnia
Respiratory, Thoracic and Mediastinal Disorders: Dyspnea
Skin and Subcutaneous Tissue Disorders: Pruritus
The following reactions occurred during titration in the clinical trials with an overall frequency of less than 1% and are listed in descending order of frequency within each system organ class.
Eye Disorders: Vision blurred, dry eye
Gastrointestinal Disorders: Abdominal pain
Injury, Poisoning and Procedural Complications: Fall
Metabolism and Nutrition Disorders: Dehydration, anorexia
Musculoskeletal and Connective Tissue Disorders: Back pain, arthralgia, joint swelling
Psychiatric Disorders: Anxiety, agitation
Renal and Urinary Disorders: Urinary retention
Respiratory, Thoracic and Mediastinal Disorders: Cough, increased bronchial secretion, dysphonia, pharyngolaryngeal pain
Skin and Subcutaneous Tissue Disorders: Hyperhidrosis
Vascular Disorders: Hot flush
Table 3 lists adverse reactions with an overall frequency of 5% or greater for the total safety database subsequent to titration during the clinical trials.
Table 3: Adverse Reactions Subsequent to Titration in
5% or More of Patients
|System Organ Class||Dosing
|General Disorders and Administration Site Conditions|
|Respiratory, Thoracic and Mediastinal Disorders|
|A patient was counted only once within each category.|
The following adverse reactions occurred during the dosing period of the clinical trial with an overall frequency of 1% or greater and are listed in descending order of frequency within each system organ class.
Cardiac Disorders: Tachycardia, sinus tachycardia
General Disorders and Administration Site Conditions: Edema peripheral, fatigue, pyrexia, chest pain, drug withdrawal syndrome, chills, irritability, malaise, application site irritation
Injury, Poisoning and Procedural Complications: Contusion
Musculoskeletal and Connective Tissue Disorders: Back pain, arthralgia, muscular weakness
Nervous System Disorders: Hypoesthesia, lethargy, sedation, tremor, somnolence, headache, dizziness
Psychiatric Disorders: Depression, restlessness, agitation, confusional state, insomnia, hallucination, disorientation
Renal and Urinary Disorders: hypertension, hypotension
Skin and Subcutaneous Tissue Disorders: hyperhidrosis, pruritus
In a single-dose mucositis study, a group of patients with Grade 1 or 2 oral mucositis (n=9) and without oral mucositis (n=9) were included in a clinical trial designed to support the safety of SUBSYS. Two of the nine subjects with mucositis (one with Grade 1 and one with Grade 2) reported a burning sensation in the oral mucosa after treatment. Both of these events were considered mild and probably related to treatment. There was no change in grade of mucositis after treatment for any subject.
Read the entire FDA prescribing information for Subsys (Fentanyl Sublingual Spray)
Additional Subsys Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.